Biogen Inc. announced it will present new spinal muscular atrophy $(SMA)$ data at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference (March 8–11, 2026) and SMA Europe 2026 (March 11–14, 2026). The company said long-term results from the DEVOTE and ONWARD studies support benefits of a higher-dose nusinersen regimen, and it will also share new Phase 1b data for the investigational SMA therapy salanersen as Phase 3 studies begin, including the STELLAR program in infants and the SOLAR study in participants aged 15–60 years. These results have not yet been presented and are scheduled for presentation at the upcoming conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050730OMX_____CNEWS_EN_GNW9666103_en) on March 05, 2026, and is solely responsible for the information contained therein.